hematologic malignancy

Type: Keyphrase
Name: hematologic malignancy
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

ACTINIUM PHARMACEUTICALS : Pharma :ceuticals Introduces Baylor Sammons Cancer Center as Clinical Trial Site

Actinium Pharmaceuticals reported the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A.According to a media release, the center joins several other clinical trial sites currently participating in the Actimab-A ... [Published 4 Traders - Aug 13 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 1 reports

Fate Therapeutics' (FATE) CEO Christian Weyer on Q2 2014 Results - Earnings Call Transcript

OperatorWelcome to Fate Therapeutics Second Quarter 2014 Financial Results Conference Call. At this time, all participants are in a listen-only mode. This call is being webcast live on the Investors and Media section of Fate’s website at fatetherapeutics.com. ... [Published Seeking Alpha - Aug 13 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Actinium Pharmaceuticals Adds Baylor Sammons Cancer Center as Clinical Trial Site

Actinium Pharmaceuticals reported the addition of Baylor Charles A. Sammons Cancer Center as a clinical trial site for Actimab-A. According to a media release, the center joins several other clinical trial sites currently participating in the Actimab-A ... [Published Individual.com - Aug 04 2014]
First reported Aug 01 2014 - Updated Aug 01 2014 - 1 reports

Antifungal therapy may increase risk for pediatric mold infection

Treatment with antifungal therapy may be a risk factor for invasive mold infections, according to study findings in The Journal of the Pediatric Infectious Diseases Society .Rachel L. Wattier, MD, of the University of California San Francisco, and colleagues ... [Published Orthopedics Today - Aug 01 2014]
First reported Jul 30 2014 - Updated Jul 30 2014 - 1 reports

Baylor Sammons Cancer Center Joins as Clinical Trial Site for Actinium’s Actimab-A Clinical Trial

. (NYSE MKT:ATNM) ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced the addition ofM. Yair Levy, MD, Medical Director of Hematologic ... [Published Wall Street Select - Jul 30 2014]
First reported Jul 29 2014 - Updated Jul 30 2014 - 1 reports

Fate Therapeutics Announces FDA Clearance of IND for Clinical Development of PROHEMA in Inherited Metabolic Disorders

(GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. ( Nasdaq:FATE ), a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today that the U.S. Food and Drug Administration (FDA) ... [Published Crawford Financial Planning - Jul 29 2014]
First reported Jul 26 2014 - Updated Jul 26 2014 - 1 reports

Is a single positive blood culture for Enterococcus species representative of infection or contamination?

“Data on the clinical outcomes of patients with a single compared with multiple positive blood cultures for Enterococcus species is limited. We undertook a retrospective cohort study in adults with at least one positive blood culture for Enterococcus ... [Published IVTEAM - Jul 26 2014]
First reported Jul 25 2014 - Updated Jul 25 2014 - 1 reports

Pre-Exercise Participation Cardiovascular Screening in a Heterogeneous Cohort of Adult Cancer Patients

Background. The purpose of this study was to investigate the extent of pre-exercise participation (“preparticipation”) health screening in a heterogeneous cohort of adult cancer patients.Methods. Patients (n = 413) with histologically confirmed solid ... [Published The Oncologist - Jul 25 2014]
Entities: Cohort, Risk, Screening, Cancer, ACSM
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

System 'prints' precise drug dosages tailored for patients

Arun Giridhar, an associate research scientist in Purdue's School of Chemical Engineering, works with student Sierra Davis to operate a prototype system to dispense precise medication dosages tailored for specific patients, an advance in personalized ... [Published Purdue University - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Eutropics Laboratory Receives CLIA Certification

Eutropics, a privately held company developing novel diagnostic tests that provide predictive insights to cancer patient response to treatment, recently announced that its clinical diagnostics laboratory, located in Cambridge, Mass., has received CLIA ... [Published Advance for Administrators of the Laboratory - Jul 18 2014]
First reported Jul 18 2014 - Updated Jul 18 2014 - 1 reports

Well-Differentiated Thyroid Cancer: Radiation Found to Increase Risk of Secondary Hematologic Malignancy—Clinical Significance, Though, Remains to be Determined

Image ToolsFor patients with well-differentiated thyroid cancer (WDTC), use of radiation therapy increases the risk of developing a secondary hematologic malignancy by 27 percent—mainly attributable to a 32 percent increased risk associated with radioactive ... [Published Oncology Times - Jul 18 2014]
First reported Jun 12 2014 - Updated Jun 12 2014 - 1 reports

Marina Biotech Announces That Licensee Mirna Therapeutics Enrolls First Patient in Hematologic Malignancy Cohort of On-Going Trial

Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ... [Published Marketwire - Breaking News Releases - Jun 12 2014]

Quotes

Kaushik J Dave , Ph D , President and CEO of the Company stated, "We are pleased to work with Baylor Charles A Sammons Cancer Center , which is one of the largest oncology centers in the nation treating over 55,000 cancer patients every year. The selection reflects its commitment and significant experience in conducting clinical trials to evaluate the newest strategies for cancer prevention, diagnosis and treatment."
...transformative therapeutic intervention," commented Christian Weyer, M D , M A S , President and Chief Executive Officer of Fate Therapeutics. "We believe pharmacologically-optimized HSC therapeutics, such as PROHEMA, hold significant promise for improving outcomes in patients with inherited metabolic and other rare genetic disorders. FDA clearance of the PROVIDE study marks an important step towards our goal of clinically evaluating this novel treatment paradigm in the non-malignant disease setting."
...T Silver Distinguished Professor of Hematology and Medical Oncology and Associate Dean for Clinical Research at Weill Cornell Medical College. "I look forward to working with the newest SAB members as we continue to make strides to eradicate lymphoma."

More Content

All (15) | News (14) | Reports (0) | Blogs (1) | Audio/Video (0) | Fact Sheets (0) | Press Releases (0)
sort by: Date | Relevance
ACTINIUM PHARMACEUTICALS : Pharma :ceuticals In... [Published 4 Traders - Aug 13 2014]
Fate Therapeutics' (FATE) CEO Christian Weyer o... [Published Seeking Alpha - Aug 13 2014]
Actinium Pharmaceuticals Adds Baylor Sammons Ca... [Published Individual.com - Aug 04 2014]
Antifungal therapy may increase risk for pediat... [Published Orthopedics Today - Aug 01 2014]
Baylor Sammons Cancer Center Joins as Clinical ... [Published Wall Street Select - Jul 30 2014]
Fate Therapeutics Announces FDA Clearance of IN... [Published Crawford Financial Planning - Jul 29 2014]
Is a single positive blood culture for Enteroco... [Published IVTEAM - Jul 26 2014]
Pre-Exercise Participation Cardiovascular Scree... [Published The Oncologist - Jul 25 2014]
Lymphoma Research Foundation Announces New Scie... [Published Industrial Info Financials - Jul 24 2014]
System 'prints' precise drug dosages tailored f... [Published Purdue University - Jul 18 2014]
Eutropics Laboratory Receives CLIA Certification [Published Advance for Administrators of the Laboratory - Jul 18 2014]
Well-Differentiated Thyroid Cancer: Radiation F... [Published Oncology Times - Jul 18 2014]
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Variants of humanized immunomodulatory monoclon... [Published PharmCast - Apr 15 2014]
ImmunoGen Inc. Announces Favorable Initial Safe... [Published BioPortfolio - Dec 09 2013]
1
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Marina Biotech Announces That Licensee Mirna Th... [Published Marketwire - Breaking News Releases - Jun 12 2014]
Marina's SMARTICLES(R) Technology Used to Deliver First-Ever MicroRNA Oncology Compound in Human Clinical Trials ...
1
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.